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Abstract 
End goal of translational medicine is to combine disciplines and expertise to eventually promote improvement of the 
global healthcare system by delivering effective therapies to individuals and society. Well-trained experts of the trans-
lational medicine process endowed with profound knowledge of biomedical technology, ethical and clinical issues, as 
well as leadership and teamwork abilities are essential for the effective development of tangible therapeutic prod-
ucts for patients. In this article we focus on education and, in particular, we discuss how programs providing training 
on the broad spectrum of the translational medicine continuum have still a limited degree of diffusion and do not 
provide professional support and mentorship in the long-term, resulting in the lack of well established professionals 
of translational medicine (TMPs) in the scientific community. Here, we describe the Marie Skłodowska-Curie Actions 
program ITN-EUtrain (EUropean Translational tRaining for Autoimmunity & Immune manipulation Network) where 
training on the Translational Medicine machinery was integrated with education on professional and personal skills, 
mentoring, and a long-lasting network of TMPs.
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The need for translational medicine professionals 
(TMPs)
The twentieth century has been revolutionary in terms 
of biomedical discoveries and innovations in technolo-
gies, e.g. high-throughput screenings and omics. The 
large amount of knowledge so derived has great potential 
to prolong human life and enhance its quality. However, 
there is considerable concern of an insufficient transla-
tion of this knowledge into tangible products with clear 
clinical impact [1]. This gap in the translational process 
is described as the valley of death. The valley represents 
the challenges that clinicians and scientists are facing in 
the process of developing effective therapies for patients, 
resulting in only a small fraction of all efficacious phar-
macological agents in preclinical models being licenced 
after Phase III clinical testing [2]. Possible explanations 
are: (1) animal models do not correctly represent human 
diseases due to significant differences in biology [3], (2) 
overestimation of drug effects in preclinical models due 
to the higher probability of positive results to be pub-
lished [4], (3) limited well-designed clinical trials in the 
era of precision medicine [5] and (4) irreproducibility 
of scientific findings [6], which is only to a small extent 
caused by scientific misconduct [7]. Despite translational 
medicine is a priority for the scientific community, pro-
fessional figures specifically trained to facilitate the com-
plex processes of the translational medicine continuum 
remain scarce. Translation requires a bi-directional effort 
starting from the identification of clinical needs and end-
ing with the development of technology/products to be 
brought back into the clinic. Lack of translation results 
in waste of public money and resources, delay in scien-
tific progress, and therefore, loss of potential benefits for 
human health. One proposed solution to bridge the gap 
between research and clinical care is the use of an educa-
tional model based on training and professional growth 
to foster the necessary skills required for the develop-
ment of experts of the translational medicine process (i.e. 
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itinerary and are equipped to act as interfaces support-
ing efficient communication among different parties of 
the process, e.g. clinicians, regulatory affairs, companies, 
basic researchers.
Need for an educational shift in the training 
of young professionals
Dynamic change within biomedical research and health-
care requires a synchronous development of learn-
ing environments and opportunities to enhance the 
knowledge and skills of young professionals. Just like 
the acknowledged need for a shift in the general edu-
cational system gave rise to the P21 [8], a collaborative 
partnership among education, business, community and 
government leaders, the accelerated rate of changes in 
translational medicine requires a similar collaborative 
effort. The aims should be to train and support a commu-
nity of TMPs to deal with the need of producing tangible 
products for the treatment of human diseases. Despite 
there being many excellent scientists and clinicians as 
well as experts of regulatory affairs and industry, profes-
sionals that can oversee the entire translational process 
as well as shared platforms where those experts can eas-
ily connect and access each other’s information and skills 
are still scarce.
What educational innovations are required to posi-
tively impact on the translational process? First, there 
is the need to set up educational programs fostering 
the development of TMPs with multidimensional skills 
(ranging from specific competences on the translational 
process to communication, coaching, creative think-
ing, problem solving, management). Secondly, TMPs 
should avoid the “silo” mentality, a narrow outlook that 
has contributed to low efficiency and failure in science, 
but rather break down barriers and cross boundaries by 
sharing information and knowledge with other scientists, 
healthcare providers and industry [9].
Existing educational programs in translational 
medicine
Educational programs providing training, at different 
levels, related to stages of the therapeutic development 
pipeline, and addressing the needs of individuals with 
distinct roles in translational research (i.e. government, 
industry and academia) are available. Examples are the 
clinical translational science (CTS) programs developed 
in the USA for graduate and postgraduate students [10], 
and the Canadian Child Health Clinician Scientist Pro-
gram (CCHCSP), providing training for clinical research-
ers to develop knowledge and skills for a career as an 
independent scientist in child health research [11]. These 
programs support the development of the translational 
scientist identity by offering a comprehensive training on 
both ‘foundational’ skills, such as research methodolo-
gies and data management, and ‘functional’ skills, such 
as communication, ethics, leadership and teamwork 
[12]. However, these programs have a limited degree of 
diffusion and are not structured to provide peer sup-
port and mentorship in the long-term. The latter point, 
in our opinion, is an essential requirement to sustain 
group identity, and provide professional guidance as well 
as concrete help to access information or other types of 
resources related to translational medicine.
Another approach to cross the valley of death is to 
develop a community of TMPs with different skills and 
expertise that can be shared and utilized by all members. 
The Eureka Institute [13] founded in 2007, is an example 
of such a community. Currently, it comprises a world-
wide network of over 200 fellows trained in interdiscipli-
nary teamwork, open-minded thinking and principles of 
translational medicine (e.g. biology, intellectual property, 
funding, regulation and trial design) during a week-long 
course held in Siracuse (Sicily, Italy). Teaching comprises 
interactive sessions led by experts in the process of trans-
lational research, including scientific directors and deans 
of academic institutes, editors of high-impact journals, 
industry, and representatives of patient organizations. 
Fellows are trained in leadership, teamwork and com-
munication to different types of audience as well as ethi-
cal and technical principles of the translational medicine 
machinery. To maximize the learning experience, the 
training technique requires students to work together to 
design strategies and solutions to real-life issues previ-
ously encountered by experienced TMPs. This network 
of translational researchers is growing, meetings and 
seminars are routinely scheduled, news in the transla-
tional medicine field are shared on social networks and 
a database is currently under development including par-
ticipants expertise and tools as well as a section to share 
ideas for the development of joint projects. The challenge 
now lies in its long-term sustainability eventually provid-
ing TMPs access to continuously updated knowledge and 
tools.
The Marie Skłodowska‑Curie ITN model
European Union Marie Skłodowska-Curie Actions, 
named after the double Nobel Prize winning scientist for 
her work on radioactivity, support researchers working 
across all disciplines, including industrial and academic 
research studies, giving the researcher the possibility to 
gain experience abroad and develop competences use-
ful to enhance future careers. This program provides a 
remarkable tool, the innovative training network (ITN), 
allowing early-stage researchers to receive doctoral train-
ing and develop transferable skills by working on joint 
research projects within a worldwide network. One such 
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ITN, EUtrain (EUropean Translational tRaining for Auto-
immunity & Immune manipulation Network, http://
www.eutrain-network.eu), was funded in 2011 and aimed 
at training a pool of young investigators in Translational 
Medicine providing (1) education on professional and 
personal skills, (2) mentoring, and (3) long-lasting net-
work of TMPs.
EUtrain focused on patient-centred research with 
respect to diagnosis, prognosis and/or treatment of 
immune-mediated diseases. Participating fellows had 
diverse backgrounds (i.e. basic scientists, biotechnolo-
gists, medical doctors, chemists and engineers) and 
conducted 3-year research training in one of the 10 par-
ticipating academic institutes based in the Netherlands, 
Italy, Germany, United Kingdom and France, or compa-
nies (Esaote Spa, Italy; Cavadis BV, The Netherlands; Pro-
teros Biostructures GmbH, Germany). Identification of 
clinical needs provided the basis to motivate generation 
of translational solutions. EUtrain partners performed 
joint research projects combining basic immune biol-
ogy studies on the regulation of inflammation with the 
development of novel high throughput and imaging tech-
nologies to detect biological markers of disease, and inte-
grate this with clinical studies and systems biology. As an 
example, Work Package (WP) 2 aimed to identify both 
conventional and innovative biological markers for moni-
toring disease activity, progression, response to therapy 
and prognosis. WP2 included 4 joint research projects 
held by 4 early-stage researchers located in academia and 
industry, consisting of (1) develop and validate commer-
cial assays for quantification of biomarkers of inflamma-
tion, (2) perform a global proteomic screening for novel 
protein biomarkers in blood of children with inflamma-
tory diseases, (3) analyze the bias towards tolerance or 
inflammation based on functional and molecular analy-
sis of the relevant pathways, and (4) develop a biomarker 
set that may predict the long-term risk of cardiovascular 
complications.
Besides the Eureka experience, trainees received addi-
tional training in specific aspects of the translational 
process from the conception of an idea to clinical test-
ing and, ultimately, the development of a treatment for 
patients. Additionally, EUtrain fellows were coached on 
professional skills, such as communication to a scien-
tific and layman audience, collaboration, conflict solving, 
teamwork, and mentor/mentee relationships. EUtrain 
fellows experienced network-wide training events, such 
as the grant writing weekend, workshops on presentation 
skills, effective communication, moderation of scientific 
meetings, valorisation of results and intellectual property 
(IP).
Core of the training was mentorship on career and per-
sonal development, which was performed on a regular 
basis by experienced TMPs. Each career step requires 
the identification of an experienced and knowledgeable 
figure providing guidance and advice on work, career, or 
professional development (i.e. mentor); on several occa-
sions during the training it was raised awareness on the 
importance of the identification of a mentor to fulfill the 
needs of one’s life and career goals. Fellows met regularly 
in informal settings and were repeatedly exposed to these 
sessions and principles at different occasions during the 
3-year training.
Here we provide a summary of the themes that 
emerged from the survey proposed to EUtrain fellows to 
determine whether and how EUtrain helped to achieve 
their professional goals. All survey respondents (13/14) 
agreed that the program enhanced their basic and trans-
lational knowledge, and enjoyed the integrated experi-
ence where network and training merged, allowing both 
scientific and personal growth. In particular, they all 
agreed that EUtrain helped creating a solid and long-
lasting European-wide professional network as well as 
developing multidimensional skills. Thanks to EUtrain, 
fellows improved their technical competences and used 
them to answer clinical questions, got insights into the 
clinical practice, understood dynamics and objectives 
of academic and industrial research. Despite the overall 
achievement of goals, one fellow would have liked to have 
more time for training in personal and professional devel-
opment, which was instead incompatible with lab duties. 
Notably, most of the fellows would not consider them-
selves independent researchers or TMPs yet at the end 
of the training, which might be due to their early career 
stage. It would be of interest to follow-up the experiences 
of these individuals, and to explore the effects of a similar 
type of training on more senior investigators. It is impos-
sible to evaluate at this stage whether this training pro-
gram will significantly improve the future development 
of clinically useful products. However, all EUtrain fellows 
have acquired the essential tools to be able to contribute 
to this goal. Future studies need to examine career out-
comes to identity program components that effectively 
equip trainees with the skills needed to thrive in a trans-
lational environment.
Conclusions
Fragmented expertise in the translational research pro-
cess and lack of platforms designed to share knowledge 
and tools among professionals are some of the barriers 
to the development of tangible products with clinical 
impact. Only specifically trained professionals such as 
TMPs can facilitate research to cross the valley of death. 
The proposed approach to fill the existing gap in transla-
tional medicine consists in the integration of education 
within a network of professionals, allowing the sharing 
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of skills and promoting collaborative efforts. This would 
also allow TMPs to access more or newer research tools 
and keep up to date on cutting-edge technologies and 
information provided by a large network. EUtrain fellows 
are now part of an international network (i.e. Eureka) 
from which they can obtain interdisciplinary and inter-
sectoral support as well as identify a mentor for career 
guidance to ultimately attain their translational purposes. 
To close the translational gap there is urgent need of mul-
tidimensional TMPs endowed with creative and open-
minded thinking, able to work in cross-functional teams, 
and embedded in a solid community of peers providing 
career guidance, theoretical framework and technical 
support.
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